- Home
- PHAR vs ORC Comparison
PHAR vs ORC Comparison
Compare PHAR & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ORC
- Stock Information
- Founded
- PHAR 1988
- ORC 2010
- Country
- PHAR Netherlands
- ORC United States
- Employees
- PHAR N/A
- ORC N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ORC Real Estate Investment Trusts
- Sector
- PHAR Health Care
- ORC Real Estate
- Exchange
- PHAR Nasdaq
- ORC Nasdaq
- Market Cap
- PHAR 731.1M
- ORC 660.1M
- IPO Year
- PHAR N/A
- ORC 2013
- Fundamental
- Price
- PHAR $10.00
- ORC $7.15
- Analyst Decision
- PHAR Strong Buy
- ORC Hold
- Analyst Count
- PHAR 3
- ORC 3
- Target Price
- PHAR $30.00
- ORC N/A
- AVG Volume (30 Days)
- PHAR 3.6K
- ORC 3.8M
- Earning Date
- PHAR 07-31-2025
- ORC 07-24-2025
- Dividend Yield
- PHAR N/A
- ORC 20.00%
- EPS Growth
- PHAR N/A
- ORC N/A
- EPS
- PHAR N/A
- ORC 0.46
- Revenue
- PHAR $320,708,000.00
- ORC $52,240,000.00
- Revenue This Year
- PHAR $13.31
- ORC $46.17
- Revenue Next Year
- PHAR $7.68
- ORC $26.45
- P/E Ratio
- PHAR N/A
- ORC $15.59
- Revenue Growth
- PHAR 24.13
- ORC N/A
- 52 Week Low
- PHAR $6.65
- ORC $5.69
- 52 Week High
- PHAR $12.61
- ORC $9.01
- Technical
- Relative Strength Index (RSI)
- PHAR 43.61
- ORC 53.78
- Support Level
- PHAR $9.99
- ORC $7.10
- Resistance Level
- PHAR $10.59
- ORC $7.28
- Average True Range (ATR)
- PHAR 0.35
- ORC 0.11
- MACD
- PHAR -0.14
- ORC 0.02
- Stochastic Oscillator
- PHAR 7.45
- ORC 70.65
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.